<DOC>
	<DOCNO>NCT00174824</DOCNO>
	<brief_summary>To compare progression diabetic retinopathy type 2 diabetic patient mild-to-moderate diabetic retinopathy treat insulin glargine v NPH human insulin .</brief_summary>
	<brief_title>Comparison Insulin Glargine NPH Human Insulin Progression Diabetic Retinopathy Type 2 Diabetic Patients</brief_title>
	<detailed_description>Randomized , open-label assignment type 2 patient stable antidiabetic regimen treatment either insulin glargine BID NPH human insulin , baseline diabetic retinopathy severity 53/ &lt; 53 ETDRS scale , 5 year followup . Outcomes measure seven-field fundus photography baseline , 1.5 , 3,6 , 9 month , annually .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus least 1 year treat oral antidiabetic agent insulin stable dos least 3 month HbA1c 6 12 % inclusive baseline retinopathy severity exceed 53/ &lt; 53 ETDRS scale unlikely require laser surgery vitrectomy within upcoming year prior treatment insulin glargine treatment insulin analog ( eg insulin lispro aspart ) year prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Retinopathy</keyword>
</DOC>